Ovarian stimulation far assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study

A total of 346 women with normal ovulatory function was stimulated with hum an menopausal gonadotrophins (HMG) to attain ovarian stimulation for IVF or intracytoplasmic sperm injection (ICSI). Stimulation with HMG started on c ycle day 2 or 3. After 6 days of stimulation, Cetrorelix in its minimum eff ective multiple dose of 0.25 mg/day, was administered daily until induction of ovulation, In total, 333 patients (96.2%) reached the day of HCG admini stration, and 324 (93.6%) underwent oocyte retrieval, A mean of 25.2 ampoul es of HMG was applied for a mean of 10.4 days. Cetrorelix was administered for a mean time lapse of 5.7 days. The mean normal fertilization rate was 6 0% in the IVF group and 59% in the ICSI group. Seventy pregnancies were att ained, reflecting an ongoing clinical pregnancy rate of 24% per transfer. T he ongoing clinical implantation rate was 11.4%. Only three cases of raised luteinizing hormone (LH) (greater than or equal to 10 IU/I) with increased progesterone secretion (greater than or equal to 1 ng/ml) were observed af ter initiation of Cetrorelix administration, reflecting an incidence of pre mature luteinization of 0.9%. The abortion rate was 17%. The incidence of s evere ovarian hyperstimulation syndrome (World Health Organization grade II I) was as low as 0.6%.